GlassScriptPhysician profile
Mark Dawdy
NPI 1558147538
$1,198.96
in general payments reported to CMS, 2019-2025
24 companies · $1,060 in 2025
The $1,060 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $139 · 2025: $1,060.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,198.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $215.18 | 2024-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $173.45 | 2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $165.79 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Lundbeck LLC | $77.04 | 2024-2025 | Rexulti |
| Abbvie INC. | $71.07 | 2025 | |
| Antares Pharma, INC. | $54.28 | 2025 | Xyosted |
| Pfizer INC. | $52.77 | 2025 | |
| Viiv Healthcare Company | $39.59 | 2025 | Apretude |
| Phathom Pharmaceuticals, INC. | $38.76 | 2025 | Voquezna |
| Axsome Therapeutics, INC. | $36.00 | 2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $34.40 | 2024-2025 | Rexulti |
| Radius Health, INC. | $29.95 | 2025 | Tymlos |
| Ardelyx, INC. | $21.32 | 2025 | Ibsrela |
| Viatris Specialty LLC | $19.74 | 2025 | Yupelri |
| Scilex Pharmaceuticals INC. | $19.50 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $19.24 | 2025 | Strensiq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.60 | 2025 | Caplyta |
| Alnylam Pharmaceuticals INC. | $17.66 | 2025 | Amvuttra |
| Hologic Sales and Service, LLC | $17.09 | 2024 | Thinprep 2000 Processor, Aptima |
| Organon LLC | $16.77 | 2025 | Nexplanon |
| Merck Sharp & Dohme LLC | $15.72 | 2025 | Capvaxive |
| Glaxosmithkline, LLC. | $15.69 | 2025 | Trelegy Ellipta |
| Amgen INC. | $15.18 | 2024 | Evenity |
| Exact Sciences Corporation | $14.17 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Dawdy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.